CULPRIT LESION MORPHOLOGY IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI): THE HORIZONS-AMI TRIAL VH-IVUS SUBSTUDY

i2 Poster Contributions
Ernest N. Morial Convention Center, Hall F
Monday, April 04, 2011, 9:30 a.m.-10:45 a.m.

Session Title: Intravascular Diagnostics II
Abstract Category: 3. Intravascular Diagnostics
Session-Poster Board Number: 2509-556

Authors: Bernhard Witzenbichler, Akiko Maehara, Gary S. Mintz, So-Yeon Choi, Xiaofan Wu, Yong He, Ovidiu Dressler, Ecaterina Cristia, Helen Praise, Roxana Mehran, Gregg W. Stone, Charité University Medicine Campus Benjamin Franklin, Berlin, Germany, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY

Background: Characterization of culprit lesion morphology in vivo in pts with STEMI has not been performed.

Methods: HORIZONS-AMI was a dual arm factorial randomized trial in pts with STEMI. As part of a formal IVUS substudy, Virtual Histology (VH)-IVUS was performed in 166 culprit lesions in 158 pts either pre and/or post stent implantation. Fibroatheromas (FA) were lesions with >10% confluent necrotic core (NC). Those with >30° NC abutting to the lumen in 3 consecutive frames were classified as thin-cap FA (TCFA).

Results: Among 83 lesions with pre-intervention VH-IVUS, 79 (95%) were diagnosed as FA, including 56 (67%) VH-TCFAs. Of the 145 categorizable post PCI lesions, 141 (97%) contained a FA behind the stent, of which 104 (72%) and 21 (13%) had NC abutting up to the lumen or protruding into the lumen through the stent struts respectively. In addition 62 (37.3%) lesions had a TCFA at the stent edge with the majority (81%) of TCFAs continuing into the stent (Figure). These VH findings were not correlated to the pre/final TIMI flow or the presence of angiographic thrombus.

Conclusions: This study is the first to demonstrate that the lesion substrate for STEMI in humans is a fibroatheroma, most commonly a TCFA. NC also typically persists within the plaque after stenting and frequently abuts or protrudes into the lumen and/or is present at the stent edge. Further studies are warranted to determine the clinical implications of these findings.